Short answer
AtriCure, Inc. (ATRC) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $154M (up 15.0% year over year) with net income of $4M.
Q3 2026 key financials · XBRL
- Revenue
- $154M
- +15.0% YoY · +0.6% QoQ
- Net income
- $4M
- +1622.1% YoY · −54.6% QoQ
- Operating margin
- 2.8%
- Gross margin
- 77.3%
- EPS (diluted)
- $0.09
- +1000.0% YoY · −50.0% QoQ
Source: XBRL data from the AtriCure, Inc. (ATRC) Q3 2026 10-Q on SEC EDGAR. USD.
AtriCure, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $154,450, up 15.0% YoY from $134,269
- Gross margin 77.3% vs 75.5% YoY, operating margin 2.8% vs 0.2%
- Best line: pain management $28,057, up 34.6%; worst: minimally invasive ablation $5,389, down 27.5%
- Cash and equivalents $187,031, debt $61,000, unused borrowing capacity $62,750
- Outlook: 30 mm AtriClip FLEX-Mini launch expected before year-end 2026, competition and PFA adoption headwinds
Risk Factors
- No material risk-factor changes disclosed versus the December 31, 2025 10-K
- Litigation risk: SentreHEART complaint seeks up to $260,000 plus interest for alleged failure to pursue FDA approval
- Operational risk: expansion lease commenced, adding $29,622 of finance lease liabilities
- Financial risk: $61,000 ABL borrowings mature in 2029, with $62,750 unused capacity
- Market risk: international revenue totaled $79,461 through nine months, exposing results to foreign currency fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other AtriCure, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.